Status:

Do Not Prescribe (DNP)

Decision Date:

August 2025

Comments

NICE TA936 (Terminated appraisal) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments - Terminated Appraisal (Decision - December 2023)

NICE TA1084 (Terminated appraisal) Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (Decision date August 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again